Across approximately 30 current analyst price targets, individual objectives cluster in a wide band from roughly $83 on the cautious end to about $121 at the top. The arithmetic mean works out to approximately $104, which is the central target used here. Independent aggregators broadly corroborate this figure: S&P Global data places the average near $104–$105, while MarketBeat's 28-analyst average sits just under $103. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion matters more than the midpoint. Bullish firms include RBC Capital ($118, Buy), Mizuho ($115, Outperform), Needham ($114, Buy), Bernstein ($112, Outperform), and Leerink Partners ($111, Outperform). More cautious voices such as Piper Sandler ($85, Hold), Goldman Sachs (low $80s, Hold), and Deutsche Bank ($92, Hold) argue that much of the growth story is already reflected in the multiple. Barclays initiated coverage with an Equal Weight rating and a $95 target in early October, framing a neutral stance.
With the shares near $94, the move to a $104 target requires roughly 11% upside — a modest but not insignificant climb. The path runs through Medtronic's fiscal 2027 first quarter (ended July 31, 2026), which delivered revenue of $9.76 billion and net income of $1.47 billion, up from $8.58 billion and $1.04 billion a year earlier. Reported organic revenue growth of 13.7% was flattered by an extra fiscal week contributing about $570 million, but management still raised full-year organic growth guidance to 7.25%–7.75%.
Cardiac Ablation Solutions was the standout, with revenue up 88%, while cardiac rhythm management, pelvic health, and diabetes each grew about 15%. This broadening beyond a single growth engine is central to the bull case for a higher valuation, though analysts disagree on whether it justifies a re-rating.
The shares have recovered from a July 2026 low near $79 to the mid-$90s, but the $100 round-number level remains an important psychological hurdle sitting between the current price and the $104 target. Many analyst targets cluster in the $100–$118 zone, suggesting that a sustained move above $100 could be the structural step needed before the central target comes into view. A failure to hold recent gains could see the stock retest support near its earlier 2026 lows.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary in their modeling windows. Key items ahead include Medtronic's next quarterly earnings and any update to fiscal 2027 guidance, additional analyst target revisions, commentary on cardiac ablation market share, the integration of the Cornerstone Robotics investment, and broader economic data affecting hospital spending. Management's December Investor Day could also clarify the longer-term growth trajectory.
In my own research process, I often rely on AI Daily Buy/Sell Signals to track how market conditions shift for names like MDT. These AI-driven tools scan thousands of stocks and ETFs daily, producing Buy, Sell, or Hold signals that help highlight potential entry or exit points alongside traditional analysis. They have proven useful for balancing the wide analyst dispersion seen here.
The $104 central target reflects the average of roughly 30 analyst objectives spanning $83 to $121, and it implies about 11% upside from a price near $94. The bull case rests on a broadening, beat-and-raise growth story and a strengthening pipeline, while the bear case centers on valuation, competitive pressure in cardiac ablation, and execution risk. The wide target range signals genuine disagreement about how much of the recovery is already priced in. Whether Medtronic reaches $104 will depend on sustained organic growth, guidance durability, and whether investors award the stock a higher multiple — none of which is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 29 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
The 10-day RSI Indicator for MDT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 16 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDT as a result. In 43 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
MDT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 176 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 84 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (24.890) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.028) settles around the average of (0.011) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of medical technology services
Industry MedicalNursingServices